STMC-103H exhibited 64% reduction in the risk of atopic dermatitis in subjects who completed one year of treatment with strong and consistent effects across multiple efficacy endpoints and was safe ...
Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), announced positive top-line results from the phase 2 ADORED study (Allergic Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results